Three-year efficacy and safety of repeated low-level red-light therapy for myopia control: a multicentre real-world study
Chen Y, Wang W, Xiong R, Yu F, Pan S, Dong J, Zhang J, Zhu Z, Ding X, Wang B, Chen Y, Chan HH, Choi KY, Chan SSH, Zheng Y, Shi D, Aung Y, Kishi S, Ohno-Matsui K, He M
The British journal of ophthalmology · 4 citas
Cómo se estudió
- Diseño
- Estudio de cohortes (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Henry G. Leong Endowed Professorship in Elderly Vision Health
- Sin clasificar
- Global STEM Professorship Scheme
Según 2 financiadores declarados.
Publicación
- Publicado
- 2026-01-20 · Br J Ophthalmol · vol. 110 · número 9 · págs. 1028–1035
- Editorial
- BMJ
- Citado
- 9 citas · más que el 100% de estudios similares · 46.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 34 trabajos
- Acceso
- De pago
- Áreas de investigación
- Ophthalmology and Visual Impairment Studies · Retinopathy of Prematurity Studies · Retinal Development and Disorders
- Palabras clave
- Clinical trial, MEDLINE, Eye disease, Visual acuity
- MeSH
- humans, myopia, disease progression, refraction, ocular, treatment outcome, follow-up studies, visual acuity, time factors, adolescent, child, female, male, red light
20 autores
- Yanping Chen🇭🇰🇨🇳Hong Kong Polytechnic University; Sun Yat-sen University
- Wei Wang🇨🇳Sun Yat-sen University
- Ruilin Xiong🇨🇳Sun Yat-sen University
- Fang Yu · autor de correspondencia
- Shaoxin Pan🇨🇳Wannan Medical College
- Jing Dong🇨🇳Baotou Medical College
- Jian Zhang🇨🇳Sun Yat-sen University
- Zhuoting Zhu🇦🇺Centre for Eye Research Australia
- X. Ding🇨🇳Sun Yat-sen University
- Bin Wang🇨🇳Baotou Medical College
- Yanxian Chen🇭🇰🇨🇳Hong Kong Polytechnic University; Sun Yat-sen University
- Henry Ho-lung Chan🇭🇰Hong Kong Polytechnic University
- Kai Yip Choi🇭🇰Hong Kong Polytechnic University
- S. L. Chan🇭🇰Hong Kong Polytechnic University
- Yingfeng Zheng🇨🇳Sun Yat-sen University
- Danli Shi🇭🇰Hong Kong Polytechnic University
- Yuri Yin‐Moe Aung🇬🇧Imperial College London
- Shoji Kishi
- Kyoko Ohno-Matsui
- Mingguang He🇭🇰 · autor de correspondenciaHong Kong Polytechnic University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
To evaluate the efficacy and safety of repeated low-level red-light (RLRL) therapy for controlling myopia progression over 3 years in real-world settings.
Methods
This multicentre cohort study included participants currently undergoing RLRL treatment, identified from electronic medical databases in three hospitals (myopic children and adolescents aged 7-18 years, who were prescribed RLRL therapy from 1 June 2018 to 1 June 2023), using stratified random sampling based on RLRL treatment duration (≥0.5-1 year, ≥1-2 years, ≥2-3 years and ≥3 years), with approximately 90 participants in each group. All participants voluntarily received RLRL therapy twice a daily (3 min/session, ≥4-hour interval), 5-7 days/week.
Results
Among 362 participants, 90 were treated for ≥0.5-1 year (median 0.64 year), 91 for ≥1-2 years (median 1.40 years), 90 for ≥2-3 years (median 2.30 years) and 91 for ≥3 years (median 3.65 years). The satisfactory myopia control rate (defined as annual axial elongation ≤0.10 mm) was 72.53% (95% CI 62.17 to 81.37) over ≥3 years of RLRL treatment, with annual axial length change of 0.06 mm/year (95% CI 0.03 to 0.08). No subjective visual function damage was documented by best-corrected visual acuity, and no treatment duration-dependent changes in objective full-field electroretinogram were observed. A minimal, reversible optical coherence tomography change was noted in four eyes which did not impact visual function.
Conclusions
This real-world study demonstrates that RLRL therapy provides promising long-term efficacy and safety in myopia control over 3 years among Chinese myopic children and adolescents.
Trial registration number
NCT05871840.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.